James Antal, Director at CLEVELAND BIOLABS INC (CBLI), bought 5,300 shares at $1.76 ($12K) on 2012-06-15, disclosed to the SEC on 2012-07-03.
Scheduled purchase ($12k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.14 | 300 | $942 | 7.9% |
| 2 | $3.15 | 300 | $945 | 7.9% |
| 3 | $3.16 | 1,300 | $4K | 34.3% |
| 4 | $1.76 | 3,400 | $6K | 50.0% |
| Total | $2.26 avg | 5,300 | $12K | 100% |
| Filing → |
| SIGA | SELL | 2019-06-07 | $171K | — | Filing → |
| CBLI | BUY | 2013-03-18 | $6K | — | Filing → |
| CBLI | BUY | 2012-09-25 | $6K | — | Filing → |